Collegium collects $22M in venture round for tamper-resistant ER oxycodone product
This article was originally published in Scrip
Executive Summary
Collegium Pharmaceuticals, a US venture-backed company focused on building a portfolio of products for chronic pain that possess tamper-resistant features and extended release delivery, has raised $22.5 million in new financing to advance the full development of its COL-003, a Phase III product in development as a tamper-resistant, ER version of the pain reliever oxycodone (the active ingredient in OxyContin and other often-abused drugs).